tiprankstipranks
Advertisement
Advertisement
BioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability
PremiumCompany AnnouncementsBioMarin’s IMPALA Study Aims to Boost Palynziq Value With Better Tolerability
1M ago
BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia
Premium
The Fly
BioMarin’s Voxzogo and BMN 333 show impact in hypochondroplasia, achondroplasia
1M ago
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
Premium
The Fly
Ascendis Pharma ‘oversold’ following ITC development, says Oppenheimer
1M ago
Buy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
PremiumRatingsBuy Rating Reaffirmed on BioMarin as Voxzogo Skeletal Disorder Opportunity Expands; $94 Price Target Maintained
2M ago
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
Premium
The Fly
BioMarin’s Voxzogo meets endpoint in Phase 3 pediatric hypochondroplasia trial
2M ago
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
Premium
The Fly
StubHub, Jazz Pharmaceuticals upgraded: Wall Street’s top analyst calls
2M ago
BioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
PremiumThe FlyBioMarin’s BMN 401 meets 1 of 2 endpoints in Phase 3 ENPP1 trial
2M ago
Morgan Stanley Sees the S&P 500 Hitting 8,300 – 2 Stocks It Says Could Surge Alongside It
Premium
Market News
Morgan Stanley Sees the S&P 500 Hitting 8,300 – 2 Stocks It Says Could Surge Alongside It
2M ago
BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors
Premium
Company Announcements
BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100